Join Growin Stock Community!

Savara inc.SVRA.US Overview

US StockHealthcare
(No presentation for SVRA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SVRA AI Insights

SVRA Overall Performance

SVRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SVRA Recent Performance

0.66%

Savara inc.

0.05%

Avg of Sector

-0.31%

S&P500

SVRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SVRA Key Information

SVRA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SVRA Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Price of SVRA

SVRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SVRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
131146.00
PB Ratio
12.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
131146.00
PB Ratio
12.98
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SVRA's latest earnings report released?

    The most recent financial report for Savara inc. (SVRA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SVRA's short-term business performance and financial health. For the latest updates on SVRA's earnings releases, visit this page regularly.

  • How much cash does SVRA have?

    At the end of the period, Savara inc. (SVRA) held Total Cash and Cash Equivalents of 16.28M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SVRA's EPS continuing to grow?

    According to the past four quarterly reports, Savara inc. (SVRA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SVRA?

    Savara inc. (SVRA)'s Free Cash Flow (FCF) for the period is -22.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.